We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Quotient Clinical Acquires Co-Formulate

News   Dec 17, 2015

 
Quotient Clinical Acquires Co-Formulate
 
 
 

RELATED ARTICLES

Mitochondria-Nucleus Interactions Could Have Implications for Mitochondria Replacement Therapy

News

Mitochondria, the "batteries" that produce our energy, interact with the cell’s nucleus in subtle ways previously unseen in humans, according to research published today in the journal Science.

READ MORE

New Opioid Accelerates Recovery Time From Pain Compared to Morphine, Preclinical Study Shows

News

A new type of opioid doesn’t have the side effects (such as increased pain sensitivity or and increased risk of chronic pain) associated with morphine and other opioid-based painkillers, and accelerates recovery time from pain compared to morphine, according to a new preclinical study.

READ MORE

Alzheimer Therapy Proven Safe for Use in Humans in Phase I Trial

News

The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE